Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The Company's lead product, eprenetapopt (APR-246), is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator that is being developed in an oral dosage form.
Managers
Name Title Age Since
Christian S. Schade Chairman, President & Chief Executive Officer 59 2020
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP 53 2019
Eyal C. Attar, Dr. Chief Medical Officer & Senior Vice President 49 2019
Lars AbrahmsÚn, Dr. Chief Scientific Officer & Senior Vice President 62 2014
Bernd Robert Seizinger, Dr. Independent Director 63 2015
John B. Henneman Lead Independent Director 58 2020
Fouad Namouni Independent Director 51 2020
Richard Peters, Dr. Independent Director 58 2020
Michael Anthony Kelly Independent Director 63 2020
Gregory A. Korbel Chief Business Officer & Senior Vice President 44 2021
Members of the board
Name Title Age Since
Christian S. Schade Chairman, President & Chief Executive Officer 59 2020
Bernd Robert Seizinger, Dr. Independent Director 63 2015
John B. Henneman Lead Independent Director 58 2020
Fouad Namouni Independent Director 51 2020
Richard Peters, Dr. Independent Director 58 2020
Michael Anthony Kelly Independent Director 63 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 21,465,140 19,362,438 90.2% 0 0.0% 90.2%
Shareholders
NameEquities%
HealthCap AB 2,366,104 11.2%
Karolinska Development AB (publ) 1,780,691 8.40%
Consonance Capital Management LP 1,459,411 6.89%
Fidelity Management & Research Co. LLC 1,260,484 5.95%
Versant Venture Management LLC 1,259,662 5.95%
Janus Capital Management LLC 851,180 4.02%
The Vanguard Group, Inc. 710,647 3.35%
Redmile Group LLC 694,918 3.28%
5AM Venture Management LLC 619,157 2.92%
SG Americas Securities LLC 598,395 2.82%
Company contact information
Aprea Therapeutics, Inc.
535 Boylston Street
Boston, MA 02116

Phone : +1.617.463.9385
Web : http://www.aprea.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Aprea Therapeutics, Inc.
Sector Other Biotechnology & Medical Research